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Abstract
The molecular heterogeneity of acute leukemias and other tumors constitutes a major obstacle towards understanding
disease pathogenesis and developing new targeted-therapies. Aberrant gene regulation is a hallmark of cancer and plays a
central role in determining tumor phenotype. We predicted that integration of different genome-wide epigenetic regulatory
marks along with gene expression levels would provide greater power in capturing biological differences between leukemia
subtypes. Gene expression, cytosine methylation and histone H3 lysine 9 (H3K9) acetylation were measured using high-
density oligonucleotide microarrays in primary human acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)
specimens. We found that DNA methylation and H3K9 acetylation distinguished these leukemias of distinct cell lineage, as
expected, but that an integrative analysis combining the information from each platform revealed hundreds of additional
differentially expressed genes that were missed by gene expression arrays alone. This integrated analysis also enhanced the
detection and statistical significance of biological pathways dysregulated in AML and ALL. Integrative epigenomic studies
are thus feasible using clinical samples and provide superior detection of aberrant transcriptional programming than single-
platform microarray studies.
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Introduction
Regulation of gene expression involves multi-layered mecha-
nisms in which epigenetic modifications such as DNA methylation
and histone tail modifications play a major role[1,2]. Post-
translational modifications of histones at specific residues help to
determine chromatin structure and therefore accessibility to gene
promoters and regulatory regions. Amongst these marks, acetyla-
tion of lysine 9 on histone H3 (H3K9 acetylation) has been linked
to gene activation and active transcription[3,4]. Cytosine meth-
ylation at promoter regions, on the other hand, is associated with
gene silencing[5]. Epigenetic regulation of gene expression has
additional complexities; not only is the presence of specific
epigenetic marks important but their localization and density also
seem to play a crucial role[6–8].
Disruption of epigenetic regulation during malignant transfor-
mation can profoundly alter a cellular phenotype, resulting in
aberrant cellular proliferation and survival. Epigenetic dysregula-
tion is currently recognized as one of the hallmarks of cancer
[9,10]. DNA methylation at promoter regions of key negative cell
cycle regulators and DNA repair genes leads to their abnormal
epigenetic silencing in many neoplasms[5,11–14]. However, it is
not clear whether this aberrant DNA methylation pattern is
sufficient to determine gene silencing, or whether it is in fact part
of a more complex process involving chromatin remodeling factors
and changes in histone modifications[15,16].
Gene expression profiling studies have been performed with
the aim of dissecting the molecular subtypes of several neo-
plasms, in an effort to predict accurately tumor behavior and to
identify important oncogenic genes and biological pathways.
These studies have revealed the presence of unique gene
expression signatures distinguishing specific subgroups of cancers
and have served to improve our understanding of the biology of
these diseases (e.g. [17–20]). However, only part of the cellular
information is contained at the messenger RNA level, and
transcriptional activity is dependent on multiple factors. Among
these factors are epigenetic marks, such as cytosine methylation
and histone tail modifications, which help to determine and
regulate chromatin structure and function including gene
expression.
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Therefore, while gene expression studies using DNA micro-
arrays have had a great impact in the study of cancer, it is
important to recognize that there are limitations associated with
this technique. Firstly, gene expression microarrays capture a
snapshot of the cell’s transcriptome, detecting genes being actively
transcribed at the time of RNA extraction, but they do not capture
any information concerning the genes’ regulatory states and
consequently their potential for transcriptional changes in
response to stimuli. For example, a locus such as the O6-
methylguanine DNA methyltransferase (MGMT) gene is not
prognostically useful in terms of its basal expression state [21]
but the cytosine methylation status of its promoter provides an
excellent indicator of how well gliomas will respond when treated
by alkylating agents [22]. We hypothesize that biologically
significant changes in expression can be missed by expression
arrays due to technical limitations, but might be captured by
epigenomic studies by identifying genes at which promoter
cytosine methylation or H3K9 acetylation differ and testing them
with highly-quantitative techniques.
In order to test these hypotheses, we carried out genome-wide
studies for DNA methylation and H3K9 acetylation as well as
gene expression microarrays in patients with acute myeloid and
lymphoblastic leukemia (AML and ALL, respectively). These cell
types were chosen so that we could test whether the technical
approach we were exploring was feasible in typical clinical
samples, using cell types that should be markedly distinctive. We
show here that the integration of the information captured by
these different platforms results in a more comprehensive detection
of differentially regulated genes and an enhancement of the
apparent biological relevance of the findings.
Results
Multiplatform epigenomic microarray analysis can be
performed on routine leukemia clinical samples
Bone marrow aspirates from three adult patients with AML and
two patients with ALL were enriched for mononuclear cells by
Ficoll gradient separation to yield .90% leukemia blast cells (see
Table 1 for patient characteristics). Frozen aliquots of these
samples were thawed for analysis using three different microarray
platforms. Unsheared high quality genomic DNA was extracted
from 5–10 million cells for genome-wide cytosine methylation
analysis using the HELP (HpaII tiny fragment enrichment by
ligation mediated PCR) assay[23]. Ten million cells were cross-
linked by exposure to formaldehyde for ChIP-chip with a specific
antibody for histone H3 lysine 9 (H3K9) acetylation, a specific
antibody for total histone H3 and non-specific rabbit IgG. Total
RNA was extracted from 20 million cells using Qiagen’s RNeasy
mini kit for expression array analysis.
The HELP cytosine methylation analysis was performed in
triplicate for each sample. Methylation status could be assigned in
.86% of probe sets (i.e. 1–14% of probe sets failed to provide a
clear signal). The correlation between cytosine methylation profiles
in individual replicates from the same sample was r = 0.93–0.99 and
correlation amongst different patients was r = 0.78–0.91 (Figure
S1A). After initial quality control one replicate from ALL-2 was
excluded from further analysis. ChIP-chip was performed in
duplicates and the correlation between replicates was r = 0.92–
0.93, while correlation between different patients ranged between
r= 0.88–0.92 (Figure S1B). After initial quality control one
replicate from ALL-2 and one from AML-3 were excluded from
further analysis. Gene expression analysis was performed in
quadruplicate and the best two replicates for each patient were
selected based on our initial quality control (see methods section).
Correlation between replicates was r = 0.95–0.99. Correlation
between the five patients in gene expression ranged from
r= 0.84–0.96. (Figure S1C). For each platform, single locus gene
validation was performed on a subset of genes respectively by
MassArray for methylation (9 genes), by qChIP for H3K9
acetylation (10 genes), or qRT-PCR for gene expression (15 genes),
demonstrating that each microarray platform was highly accurate in
predicting the actual abundance of mRNA, DNA methylation and
histone acetylation of each gene (Figures S2A, S2B and S2C).
Taken together, these data indicate that multi-array analysis is
robust and feasible in frozen leukemia patient samples.
ALL and AML have distinct DNA methylation profiles
Although aberrant DNA methylation is known to occur in
human leukemias,[24] it is not known whether (as has been shown
for gene expression profiling) different types of leukemia have
specific and distinct profiles of promoter DNA methylation. All
five leukemia samples presented a bimodal distribution of DNA
methylation, with approximately two-thirds of HpaII fragments
detected as methylated and one-third as hypomethylated. In order
to determine whether AML and ALL samples display distinct
DNA methylation signatures, we performed unsupervised cluster-
ing of HELP array data. The DNA methylation profiles from
leukemia samples were submitted to three different unsupervised
clustering algorithms including hierarchical clustering (HC),
principal component analysis (PCA) and correspondence analysis
Table 1. Patients’ characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (yrs) 54 82 25 44 53
Gender Female Female Male Female Female
Diagnosis ALL ALL AML AML AML
Karyotype t(9;22)(q34;q11) t(9;22)(q34;q11.2),
add(16)(q21), 220, +mar
46,XY, t(5;21;8)(q15;q22;q22) NA t(10;11)(q22;q23)
Immunophenotype Early Pre-B ALL with
co-expression of
CD33 and CD13
Early Pre-B ALL with
co-expression of CD33
and CD13
Undifferentiated AML CD65
negative, CD19 positive,
CD11a negative
CD11b Positive, co-
expression of CD7
Undifferentiated AML,
CD65 negative
Molecular
characterization
BCR-ABL p190 (e1a2) BCR-ABL p190 (e1a2) AML1/ETO positive negative by RT-PCR for
BCR/ABL, AML1/ETO,
CBFbeta/MYH11, MLL-TD
and FLT3-ITD
negative by RT-PCR for
BCR/ABL, AML1/ETO,
CBFbeta/MYH11, MLL-TD
and FLT3-ITD
doi:10.1371/journal.pone.0001882.t001
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(COA). Each of these methods detects global differences between
samples as distances and represents them in different ways. HC of
HELP profiles separated the cases into two separate nodes
containing either the ALLs or the AMLs. (Figure 1A). Similar
to HC, PCA yielded a clear difference between AML and ALL
(Figure S3A). COA revealed an identical node structure as HC
and allowed us to generate a list of genes differentially methylated
between AML and ALL (Figure 1B). All three of these clustering
methods demonstrated that promoter methylation signatures
could accurately segregate the samples into the AML and ALL
categories. Since there are 10 distinct ways in which 5 samples can
be divided into two groups of 2 and 3 samples each, it was
calculated that there was a 1 in 10 chance that this separation of
the samples by lineage was due to chance.
Histone 3 lysine 9 acetylation profiles distinguish ALL
from AML cell types
In contrast to DNA methylation, acetylation of histone H3 on
lysine 9 has been associated with genes that are transcriptionally
active[3,4]. We predicted that the epigenetic information contained
in the H3K9 acetylation status of genes would be informative
regarding the biological phenotype of AML and ALL. H3K9 acetyl
ChIP-chip performed robustly using patient samples and revealed a
bimodal distribution in which approximately one-third of all gene
promoters represented displayed H3K9 acetylation. In order to
determine whether H3K9 acetylation status could distinguish AML
from ALL cells, unsupervised clustering (HC, PCA and COA) was
again performed (Figures 1C & 1D and Figure S3B). All three
methods yielded a similar segregation of the cases into two classes
consistent with their biological lineages. Taken together, these data
indicate that AML and ALL are epigenetically distinct cell types
that can be classified through genome-wide analysis of DNA
methylation and H3K9 acetylation.
DNA methylation, histone acetylation and gene
expression profiling identify distinct cohorts of genes in
AML and ALL cells
We next asked whether genes detected as robustly differentially
methylated, H3K9 acetylated and expressed by microarray
Figure 1. Epigenomic platforms readily classify leukemia samples according to lineage. Unsupervised clustering of DNA methylation by
HELP and H3K9 acetylation ChIP-chip data succeeded in accurately segregating the samples according to their lineage. Panel A: Dendrogram
representing the result of hierarchical clustering of leukemia samples using DNA methylation data. The scale on the left represents the correlation
distance metric. Panel B: Heatmap of top 150 genes from the first principal component of correspondence analysis, which separated ALL samples
from AML. Genes are shown on the rows and samples on the columns, and data were row-centered. Low values corresponding to greater
methylation are represented in blue and high values corresponding to less methylation are in red. Panel C: Hierarchical clustering of leukemia
samples using H3K9 acetylation ChIP-chip. Panel D: Heatmap of top 100 genes from the first principal component of correspondence analysis, which
separated ALL samples from AML. Low values corresponding to less H3K9 acetylation are represented in blue and high values corresponding to
greater H3K9 acetylation are in red.
doi:10.1371/journal.pone.0001882.g001
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analysis would be overlapping or complementary. In order to
identify the genes that most significantly distinguish AML from
ALL cells in terms of gene expression, H3K9 acetylation and DNA
methylation, we performed a supervised analysis using a T-test,
with lineage as the dichotomous variable. For DNA methylation
data, a second condition requiring a minimum difference of 1.5
between the two sample means was implemented in order to
maximize the capture of biologically significant changes in
methylation (Figure 2A). Analysis was restricted to the 17,180
genes that are represented on all three microarrays platforms used.
Using this common denominator, 1,359 genes were identified as
differentially expressed between the two types of leukemia at a
significance level of p,0.02. Histone H3 lysine 9 acetylation, on
the other hand, identified 374 genes at the same level of
significance, while 190 genes were classified as differentially
methylated (Figures 2B, 2C and 2D). Overlap between gene
expression and H3K9 acetylation signatures included 45 genes,
overlap between DNA methylation and gene expression included
13 genes, while DNA methylation and H3K9 acetylation
overlapped on 3 genes. All three platforms overlapped on only 1
gene: the metallopeptidase LMLN. These partially overlapping
signals probably result from both the distinct biological nature of
the parameters being measured by each different platform as well
as from unique technical limitations that affect each one. Thus,
gene signatures obtained using epigenomic and gene expression
profiling can provide complementary sets of genes (Figure 2E),
resulting in a greater set of unique biological features being
captured, which would otherwise be missed by any single platform.
H3K9 acetylation widely correlates with gene expression
Acetylation of lysine 9 on histone H3 has been associated with
actively transcribed genes [3,4], but the degree of association is
unknown at the genome-wide level in leukemia patients. In order
to define with greater precision the quantitative relation between
variation in histone acetylation and gene expression, we studied
the correlation between promoter H3K9 acetylation and gene
transcript abundance. Since correlations between variables are
degraded rapidly by increasing noise levels, we selected genes with
a SNR.2.5. The median correlation between H3K9 acetylation
and gene expression over 393 genes with a SNR.2.5 in both
measures was 0.86 (Figure 3A). In order to test whether these
findings could be simply due to an artifact of the small sample size,
we developed a statistical model in which we selected genes that
were as much as possible statistically independent and then re-
calculated the correlations after several sample-label permutations.
This analysis showed that the probability of obtaining the observed
correlations by chance was astronomically small (p,1 in 108) (see
supplementary methods). Therefore, the degrees of H3K9
acetylation and gene transcript level are quantitatively tightly
linked in these leukemic cells.
Since microarray measures are inherently corrupted by noise,
we hypothesized that the true underlying biological correlations
between gene expression and H3K9 acetylation were much
greater than captured through a simple correlation of high SNR
genes. In other words, that this epigenetic modification could
detect differences in gene expression missed by expression arrays.
In order to test this hypothesis, we randomly selected a group of
five genes (FER, HOXA1, DOCK5, LT4R1 and PAX5) among those
that presented differential H3K9 acetylation with an SNR.2.5,
but that were not detected as differentially expressed by
microarray analysis. A more precise measurement of transcript
abundance of these genes was performed by qRT-PCR, which
revealed that differential expression was significantly greater than
had been detected by microarray: the range of fold difference
Figure 2. Gene expression, DNA methylation and H3K9 acetylation identify partially overlapping genes signatures. Supervised
analysis of the three datasets using a T-test and leukemic lineage as the dichotomous variable identified partially overlapping gene signatures
distinguishing between ALL and AML. Panel A: Plot of differences between sample means (x axis) vs. 2log10 p values (y axis), illustrating the two
criteria required for significance in HELP data. Blue dots represent genes with p,0.02 and a difference in sample means.1.5. Panel B: Heatmap of
gene signature identified using gene expression arrays. Genes are shown on the rows and samples on the columns, and data were row-centered. Low
values of gene expression are represented in blue and high values are in red. Panel C: Heatmap of gene signature identified using H3K9 acetylation
arrays, constructed as described for Panel A. Low values corresponding to less H3K9 acetylation are represented in blue and high values
corresponding to greater H3K9 acetylation are in red. Panel D: Heatmap of gene signature identified using DNA methylation (HELP) arrays,
constructed as described for Panel A. Low values corresponding to greater methylation are represented in blue and high values corresponding to less
methylation are in red. Panel E: Venn diagram illustrating overlap between the three gene signatures.
doi:10.1371/journal.pone.0001882.g002
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between ALL and AML by gene expression array was 1.0–2.8 and
by qRT-PCR 2.3–45.6 (Figure 3B). Furthermore, the correlation
between H3K9 acetylation and gene expression measured by
qRT-PCR was considerably higher than between H3K9 acetyla-
tion and array gene expression (r = 0.74 vs. 0.42, respectively)
(Figures 3C and 3D). The data suggest that significant
differential gene expression can be missed by expression micro-
array analysis but recaptured by integrating functionally relevant
epigenetic modifications such as H3K9 acetylation. These data
also confirm the close association between transcriptional
activation and histone acetylation at the genome-wide level.
Genome-wide promoter methylation status shows an
overall inverse correlation with gene expression and
H3K9 levels
Promoter DNA methylation is generally believed to be
associated with gene silencing, although it is not clear whether
this can be generalized in a whole genome analysis. Therefore, we
determined the relationship between gene expression and DNA
methylation in our set of leukemia patient samples. As before, high
SNR genes (.2.5) were selected for this analysis. Correlation of
expression and DNA methylation among these genes revealed a
bimodal distribution where two-thirds of genes displayed a strong
positive correlation between expression and the log HpaII/MspI
ratio (which translates biologically into an inverse correlation
between gene expression and DNA methylation levels) where the
peak value was r = 1.0. The remaining one-third of genes showed a
weak negative correlation (peak at r =20.5) (Figure 4A). The
presence of a strong correlation between gene expression and log
HpaII/MspI ratio was still clearly detected even at SNR cutoffs of
1.3. These data indicate that for a majority of promoters, DNA
methylation is strongly associated with gene silencing. A similar
bimodal distribution was detected for the correlations between
DNA methylation and H3K9 acetylation. The largest peak of
the correlations was found at r = 1.0. A second and less defined
peak that represented a smaller population of genes was
found with a slightly negative correlation (around r =20.5)
(Figure 4B). While the first peak is to be expected, representing
silenced genes with methylated promoters lacking the H3K9ac
mark associated with active chromatin, the second peak may be
Figure 3. H3K9 acetylation correlates with active gene expression and can help rescue genes from within the noise level of gene
expression arrays. Panel A: Smoothed histogram of gene-by-gene correlation between gene expression and H3K9acetyl ChIP-chip for genes
displaying a high SNR on both platforms. Median correlation was r = 0.84. Panel B: Comparative fold difference in mRNA levels (y axis) as detected by
gene expression arrays and qRT-PCR for five genes that displayed differential H3K9 acetylation but had not been detected as differentially expressed
on the microarrays. Panels C and D: Correlation for those same 5 genes between H3K9 acetylation levels (y axis) and gene expression levels (x axis)
measured by either gene expression arrays (panel C) or qRT-PCR (panel D). Correlation between H3K9 acetylation and gene expression was
significantly higher when the latter was measured by qRT-PCR, indicating that H3K9 acetyl ChIP-chip could predict genuine differences in gene
expression levels that were missed by gene expression arrays, probably due to relative compression of the signal on the gene expression arrays as
demonstrated in panel B.
doi:10.1371/journal.pone.0001882.g003
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Figure 4. Promoter DNA methylation shows genome-wide inverse correlation with gene expression and H3K9 acetylation: Panel A:
Smoothed histogram of gene-by-gene correlations between log(HpaII/MspI) values and gene expression, showing a positive correlation between the
two measures for the majority of genes, which translates into a negative biological correlation (i.e. higher promoter methylation correlates with lower
gene expression). Panel B: Smoothed histogram of gene-by-gene correlations between log(HpaII/MspI) values and H3K9 acetylation, showing a
positive correlation between the two measures for many of the genes, which translates into a negative biological correlation (i.e. higher promoter
methylation correlates with lower promoter H3K9 acetylation). Panel C: Graphical representation of the data from all three platforms for one of the
cases (AML.2) as custom tracks in the UCSC genome browser[40]. Four representative genes are shown here to illustrate the correlation between the
three platforms. H3K9 acetylation data (in blue) is represented as the ratio of the signal between the H3K9 acetyl channel and the input channel; DNA
methylation (in red) is represented as log(HpaII/MspI), so that a negative deflection corresponds to a methylated HpaII fragment while a positive one
corresponds to a hypomethylated fragment; finally, gene expression data (in green) is represented as median-centered log2 of RMA-normalized
intensities.
doi:10.1371/journal.pone.0001882.g004
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explained by a number of different factors (see discussion). Overall,
the results demonstrate that for most genes, the presence of high
levels of methylation corresponds with repression, while high levels
of acetylation correspond to activation, as exemplified in
Figure 4C.
Integration of histone acetylation and gene expression
profiling synergistically enhances the detection of
differentially regulated genes between AML and ALL
samples
Taken together with the fact that H3K9 acetylation and gene
expression capture different cohorts of genes, the above findings
led us to predict that integrating the measurement of individual
gene variation captured by H3K9 acetylation and gene expression
profiles would recover biologically significant differences missed by
both platforms when considered independently of each other. In
order to determine if this was the case, we tested whether
integration of gene expression and H3K9 acetylation could
enhance the discovery of genes that discriminate between AML
and ALL cells. As mentioned above, a T-test analysis (p,0.02
(absolute t score.4.5)) identified 1,359 differentially expressed
genes and 374 differentially acetylated, with an overlap of 45 genes
(Figure 2D). We next looked for genes that did not meet these
criteria for significance on either platform, but that were
marginally significant for both of them (p.0.02 and ,0.14;
absolute t score,4.5 and .2 with both t scores displaying the
same direction). Applying these criteria allowed identification of an
additional 382 genes that are likely to be discriminative between
ALL and AML (Figures 5A and 5B). Since the noise in each
platform is expected to be random, genes that in both platforms
manage to reach a borderline level of significance are unlikely to
be due to random chance. Based on the integration of their
individual t-scores, the probability that such genes are differen-
tially regulated is increased to p,0.01 (p,(0.142)/2). Nine genes
(6 test and 3 negative controls) were chosen for validation by single
locus quantitative ChIP (qChIP) and qRT-PCR. All six test genes
were found to be both differentially H3K9 acetylated (Figure 5C)
and differentially expressed (Figure 5D), while none of the
negative controls were found to show any significant difference by
either qChIP or qRT-PCR. Due to the limiting amount of sample
available we were unable to perform replicate PCR runs, but each
qPCR experiment was itself ran in triplicate. The data suggest that
integrated analysis captures biological differences between tumors
otherwise missed by independent analysis of gene expression or
histone acetylation.
Integration of DNA methylation and gene expression
profiling has an additive effect on the detection of
differentially regulated genes between AML and ALL
samples
We next wished to determine if DNA methylation profiles, like
H3K9 acetylation, could enhance the capture of differentially-
regulated genes. The same analytical approach to the integration
of gene expression and DNA methylation was used to quantify to
what extent these two platforms reinforced each other in the
discrimination of leukemic lineage of our samples. An initial
significance level of p,0.02 (absolute t score.4.5) was once again
chosen, but an additional requirement of a difference between the
two means greater than 1.5 was applied to the methylation data as
described above. In this way, 1,359 genes were differentially
expressed and 190 were differentially methylated between ALL
and AML cells with an overlap of 13 genes. In order to test
whether the two platforms reinforced each other, we examined
how many genes were consistently marginally significant on both
platforms (p.0.02 and ,0.14; absolute t score,4.5 and .2).
However, in order to ensure a potentially biologically relevant
difference in methylation, we once more had an additional
criterion of a minimum difference between the sample means.1.5
for the methylation data. When these criteria were applied to the
integration of gene expression and DNA methylation we did not
find a significant number of additional genes. However, when
qRT-PCR was performed on a subset of genes (eight genes) that
were identified as differentially methylated but that were not
predicted as differentially expressed on the arrays, significant
actual differences in mRNA levels between ALL and AML cells
were found for all of these genes. This level of differential gene
expression by qRT-PCR was comparable to that measured for
genes that had been successfully identified as differentially
expressed by the expression arrays (Figure 6A and 6B). These
results suggest that the HELP platform is capable of rescuing
differentially expressed genes. However, it does so in an additive
fashion with gene expression arrays as opposed to the synergistic
results obtained with the integration of gene expression and H3K9
acetylation.
Integration of platforms improves identification of
biological pathways that are differentially regulated in
AML versus ALL cells
Our next goal was to determine whether over-representation of
particular gene networks and canonical pathways could be found
among the genes identified by the different platforms. For this
purpose we used the Ingenuity Pathway Analysis software
(Redwood City, CA). We compared and contrasted the biological
gene networks captured as being differentially regulated in AML
versus ALL cells by the three different platforms compared with
those captured by integrated analysis. We found that the top
networks captured by each of the three individual platforms
yielded smaller and less directly affected networks centered in part
around HoxA9 and APP in H3K9 acetylation, TNF and NFkB in
cytosine methylation, and TERT and NFkB in gene expression
(Figure S4A). In contrast, the integrated analysis captured gene
networks which were clearly centered around TNF and TP53,
including multiple directly involved genes associated with the
central node (Figure S4B). In addition, networks of likely
pathological importance (such as the one centering around
MYC) were completely missed by the single platforms but were
rescued when the data for the three platforms were integrated
(Figure S4C). This result demonstrates that the integration of
data from gene expression and epigenetic platforms not only
rescues genes that are missed by either platform alone, but may
also enhance their power to more accurately define the most
highly affected biological pathways.
Likewise, the integrated analysis provided a more statis-
tically significant capture of canonical pathways (e.g.
p= 9.56e210 for the TP53 signaling pathway, p= 2.336e29 for
the protein ubiquitylation pathway and p=4.036e29 for the
WNT-b catenin signaling pathway) than any single platform
(Figure 7A and Table 2), and rescued to the analysis another
group of pathways that would otherwise have been missed (e.g. the
PI3K/AKT signaling pathway (p = 3.276e27) and the chemokine
signaling pathway (p= 1.066e23)) (Figure 7B, Table 3 and
Table S1). These data suggest that integrative analysis provides a
superior platform for hypothesis-generating experiments and
potentially greater accuracy in detecting the most relevant
biological processes that distinguish different tumors from each
other.
Integrative Epigenomic Study
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Discussion
Histone modifications and DNA methylation play a critical role
in regulating gene expression by modifying the chromatin
structure of genes and recruiting additional regulatory factors.
Our work is based on the hypothesis that a truly integrated
epigenomic analysis could yield superior insight into the
transcriptional programming of cancer cells beyond that obtained
by simply measuring abundance of mRNAs through expression
microarrays, since epigenetic modifications will capture informa-
tion not only from genes being actively transcribed, but they will
also reflect the availability for transcription by informing on the
chromatin structure at specific loci. As proof of principle, we
selected two functionally validated epigenetic marks–cytosine
methylation and histone 3 lysine 9 acetylation–in addition to
standard gene expression arrays and tested their ability to identify
gene regulatory differences between the AML and ALL cell types.
First, we demonstrate that such multiplatform epigenomic studies
can be readily performed in enriched leukemia cells from standard
clinical trial patient specimens. Second, using a novel approach for
integrated analysis, we demonstrate that not only is there a
functional relationship between gene expression and epigenetic
marks but, more importantly, that these platforms synergize to
provide a more complete and comprehensive analysis of
transcriptional programming in human cells. Some of the
strengths of this study include the rigorous quality control steps,
the use of a powerful DNA methylation platform on specially
designed high density oligonucleotide microarrays, the use of
primary patient materials, the performance of the three different
assays using the same type of 50-mer high density oligonucleotide
arrays in multiple replicates and the extensive single locus
validation.
Recently DNA methylation microarrays have been used to
study acute leukemias as well as other malignancies. Groups of
hypermethylated genes have been identified by such studies in
AML cell lines [25] as well as in ALL patient samples [26]. Thus,
Figure 5. Gene expression and H3K9 acetylation synergize to increase the number of differentially expressed genes identified.
Panel A: Dot plot of t scores from T-test for gene expression (x axis) and H3K9 acetylation (y axis). 1,359 genes were identified as differentially
expressed and 374 as differentially H3K9 acetylated, with absolute t scores.4.5 (p,0.02). 44 genes crossed the threshold for both assays (upper
right). 83 genes that passed H3K9 acetylation threshold displayed marginal t scores (.2 and ,4.5) for expression, while 154 genes that passed
expression threshold displayed marginal t scores (.2 and ,4.5) for H3K9 acetylation. Differential expression of the former genes was validated as in
Fig 4. Combining genes with marginal t scores (.2 and ,4.5) for both platforms simultaneously yielded an additional 382 genes with positive
correlation that would have been missed by both platforms (central square, red). For illustrating purposes, points corresponding to gene expression t
scores.8 or H3K9 acetylation t scores.7 were excluded from the figure. Panel B: Bar graph illustrating synergism between the gene expression and
H3K9 acetylation analyses. 1314 genes were identified only by gene expression, 329 by H3K9 acetylation alone, and 44 genes were captured by both
platforms. After the integrated analysis, an additional 382 genes were identified. Panels C and D: Validation of fold enrichment for H3K9 acetylation
by qChIP (panel C) and fold difference in expression by qRT-PCR (panel D) of 9 genes (6 test and 3 negative controls) identified by the integrated
analysis that had been previously missed by both.
doi:10.1371/journal.pone.0001882.g005
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the integration of genetic and epigenetic platforms seems only
natural, since individually both types of platforms have proven to
capture biologically relevant information. Along these lines, some
groups have begun to investigate the potential to be found in the
combination of information from different microarray platforms.
Shi et. al. used a CpG island microarray containing 1507
expressed CpG island sequence tags to carry out a triple analysis
of histone acetylation, DNA methylation and gene expression in
an ovarian cancer cell line treated with trichostatin A and 59-
deoxyazacytidine. While they were able to detect a functional
interaction between histone acetylation and DNA methylation,
they could not demonstrate an overall correlation between
changes in epigenetic modifications and changes in expression
levels [27]. Wu et. al. used a combination of ChIP-chip for H3K9
modifications and Differential Methylation Hybridization (DMH)
on a 9.2 K mouse promoter array and showed an inverse
correlation between H3K9 acetylation and DNA methylation,
while no significant correlation could be found between DNA
methylation and H3 dimethyl-K9 at the promoter level[28]. In
our study, however, we propose the use of a combination of three
different high-density genomic and epigenomic platforms for the
in-depth analysis of their relationship in the context of human
cancer specimens.
Posing a simple biological question–that is the differentiation
between cell types in a sample set–we determined first by carrying
out a systematic unsupervised clustering analysis that epigenomic
platforms can be readily used for profiling and classification of
leukemia clinical samples. Moreover, the combination of DNA
methylation and H3K9 acetylation to gene expression data
resulted in a significantly larger number of genes being identified
that distinguished ALL from AML samples. Since each one of
these platforms is affected by unique technical limitations, it is not
surprising that they would result in the detection of only partially
overlapping cohorts of genes. The existence of such limitations was
confirmed by the fact that restricting the analysis to the subset of
genes that displayed high signal to noise ratios on any two
platforms (i.e. those genes that we can be certain were accurately
measured by both platforms) resulted in a high degree of
correlation between the different measures.
Furthermore, we hypothesized that this technical limitation due
to the presence of noise in gene expression arrays was significantly
affecting our ability to detect genuine differences in mRNA levels.
By looking at a group of genes that displayed a significant
difference between ALL and AML in either H3K9 acetylation or
DNA methylation levels but did not display significant differences
on gene expression arrays we found that when the mRNA levels of
these genes were measured by qRT-PCR, an underlying
difference in gene expression could be readily detected. Thus,
we were able to confirm that there is an important degree of loss of
information when carrying out genome-wide studies by gene
expression microarrays alone, and that this information can be
recovered by the integration of epigenetic data, reflecting the
additive benefit obtained from such an integrated approach.
However, our main goal was to investigate whether gene
expression and epigenomic microarrays were capable of reinforc-
ing each other. Our data show that it is possible to further harness
the power of integrated epigenomics to identify differentially
regulated genes, since genes missed by both gene expression and
epigenetic profiling could be recovered for analysis by taking
advantage of the tendency of gene expression profiling to correlate
positively or negatively with epigenetic marks. For this we looked
for genes that were marginally below the significance threshold on
gene expression and H3K9 acetylation and for which both
measures behaved concordantly. Using these new criteria, an
additional 382 genes were identified that had been missed by
both platforms. Careful single locus validation of randomly
selected genes from this cohort confirmed such genes to be
genuinely differentially acetylated and expressed, thus demon-
strating the synergistic power of this integrative analysis.
We propose that the additive and/or synergistic ability of
integrative genomics and epigenomics to capture differentially-
regulated genes in human clinical samples will enhance under-
standing of disease pathogenesis when carried out in an adequately
designed study. The current study used the extreme comparison of
ALL with AML clinical samples to demonstrate proof of principle
of the approach. However, even with limited numbers of samples,
the integrated analysis captures gene networks missed by single
platforms, improves the level of confidence in gene networks which
were only partially recognized by single platforms, and may center
networks more completely around critical mediators of tumori-
genesis so that subsequent functional studies could focus on gene
products most likely to occupy central roles in the biology of the
specific tumors.
Figure 6. DNA methylation identifies differentially expressed
genes missed by gene expression arrays. Panel A: Fold difference
in gene expression by qRT-PCR between ALL and AML in a subset of
genes identified as differentially methylated but not as differentially
expressed (left), a group of genes that had been identified as
differentially expressed but not differentially methylated (center), and
in a group of genes that had not been identified as either differentially
expressed nor differentially methylated. Panel B: Table showing the
median, maximum and minimum values in fold difference for the three
groups, reflecting how a subgroup of genes that is missed by gene
expression arrays but identified by DNA methylation display compara-
ble differences in gene expression levels when using a more sensitive
technique such as qRT-PCR.
doi:10.1371/journal.pone.0001882.g006
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In summary, our simple approach for integrated analysis shows
a functional relationship between gene expression and epigenetic
marks and, more importantly, demonstrates that these platforms
synergize to provide a more complete and comprehensive analysis
of transcriptional programming. We predict that when applied to
large cohorts of patients enrolled in clinical trials, this integrated
epigenomics approach will provide more accurate disease
classification and more powerful prognostic information, which
could be then used to design improved risk adapted and targeted
therapy clinical trials.
Figure 7. Integration of data from all three platforms enhances the biological information captured. Panel A: Bar graph comparing the
significance level of enrichment (y axis: 2log(p-value)) for genes within specific canonical pathways for the integrated analysis and the individual
platforms. Panel B: Bar graph showing a subset of canonical pathways that were detected as significant by the integrated analysis, but that had
been missed by the individual platforms.
doi:10.1371/journal.pone.0001882.g007
Table 2. Enrichment of specific canonical pathways by the integrated analysis and the individual platforms
Pathway
Integrated analysis
(p value)
Gene expression
(p value)
H3K9 acetylation
(p value)
DNA methylation
(p value)
TP53 signaling 9.526e210 2.76e26 4.96e22 1.36e22
Protein ubiquitylation 2.336e29 2.086e26 1.86e21 3.16e21
WNT-b catenin signaling 4.036e29 1.56e23 4.86e21 4.26e23
G1/S checkpoint regulation 5.86e29 1.26e25 – 1.16e21
TGFb signaling 6.996e29 6.36e23 7.776e24 1.86e21
doi:10.1371/journal.pone.0001882.t002
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Materials and Methods
Leukemia samples
Specimens were obtained from 5 patients diagnosed with ALL
(2 cases) or AML (3 cases). All patients had signed informed
consent. Use of the ALL samples was approved through the
Institutional Review Board (IRB) of Our Lady Of Mercy Cancer
Center and use of the AML samples was approved through the
Eastern Cooperative Oncology Group IRB for the E1900 clinical
trial. Furthermore, the study was also approved by the Albert
Einstein College of Medicine’s Institutional Review Board.
Mononuclear cells were isolated from heparinized bone marrow
or peripheral blood specimens by ficoll-hypaque density centrifu-
gation. The cells were washed twice in phosphate-buffered saline
and subsequently frozen at a concentration of 40 million cells/mL
in 90% fetal bovine serum and 10% dimethylsulfoxide. Charac-
terization of antigen profiles by multiparameter flow cytometry
was performed on mononuclear cells prior to freezing. Antibody
binding was evaluated on a FACSCalibur using the CellQuest
software program (Becton-Dickinson, Mountainview, CA). The
patient characteristics are summarized in Table 1.
Genomic DNA extraction
Genomic DNA was extracted from 5–106106 cells following a
standard phenol-chloroform protocol followed by an ethanol
precipitation and resuspension in 10 mM Tris-HCl pH 8.0.
Total RNA extraction
Total RNA was extracted from 206106 using an RNeasy Mini
kit from Qiagen (Valencia, CA), eluting twice in 30 mL of RNAse-
free water.
Chromatin Immunoprecipitation Assay (ChIP)
106106 bone marrow cells were resuspended in 10 mL of
DMEM and fixed with 1% formaldehyde at room temperature for
10 minutes. Reactions were quenched with 0.125 M glycine for
5 min, and the cells washed twice in cold PBS. Cells were lysed in
1.3 mL of lysis buffer (1% SDS+50 mM Tris-HCl
pH 8.1+10 mM EDTA pH 8.0+protease inhibitors) on ice for
10 minutes and sonicated using a Branson microtip sonicator at
45% amplitude (Fisher scientific, Pittsburgh, PA) in order to
achieve chromatin fragmentation to an average of 500 bp.
Chromatin was pre-cleared with 100 mL of Protein A agarose
beads (Roche, Indianapolis, IN) for 2 hours at 4uC, and then
diluted 10-fold in dilution buffer (1.1% Triton X-100+0.01%
SDS+167 mM NaCl+16.7 mM Tris-HCl pH 8.1+1.2 mM ED-
TA+protease inhibitors). One hundred microliters were set apart
for the input sample. Immunoprecipitation (IP) reactions in
chromatin from 16106 cells were carried overnight at 4uC with
either 2.5 mg of anti-acetylated histone H3 lysine 9 antibody
(Upstate, Catalog #: 07-352, lot: 31388) or an equal amount of
IgG isotype control (Jackson ImmunoResearch). On the following
day immune complexes were recovered by adding 25 mL of
protein A agarose beads to each reaction, incubating at 4uC for
45 minutes and then spinning down at 3000 rpm. Each sample
was washed 5 times, 10 minutes each time, as follows: 16 low salt
wash (0.1% SDS+1% Triton X-100+2 mM EDTA+20 mM Tris-
HCl pH 8.1+150 mM NaCl), 16 high-salt wash (0.1% SDS+1%
Triton X-100+2 mM EDTA+20 mM Tris-HCl pH 8.1+500 mM
NaCl), 16 LiCl wash (0.25 M LiCl+1% NP-40+1% deoxychola-
te+1 mM EDTA+10 mM Tris-HCl pH 8.1) and 26TE pH 8.0
washes (10 mM Tris-HCl+1 mM EDTA). DNA from each of the
IPs and the input sample was eluted twice for 20 minutes at room
temperature in 100 mL of elution buffer (1% SDS+0.1 M
NaHCO3) followed by an overnight incubation at 65uC to reverse
the cross-linking. DNA samples were cleaned using a QIAquick
PCR purification kit (QIAGEN, Valencia, CA) using the
manufacturer’s protocol, but using 30 mL of elution buffer for
the final elution from the column. Enrichment was calculated by
quantitative real-time PCR in a DNA Engine Opticon 2 real-time
thermocycler from Biorad (Hercules, CA) using primers directed
against the promoter regions of the CD10, CD20, CD33 or MPO
genes (for primer sequences see Table S2). Specific enrichment
for H3K9ac was determined using the DDC(t) method as
previously described[29]. Samples were amplified using a
ligation-mediated PCR protocol as previously described[30] and
maintenance of enrichment was verified by quantitative PCR prior
to submission for labeling and hybridization onto the NimbleGen
human HG17 promoter tiling oligonucleotide microarray (2005-
04-18_HGS17_min_promoter_set; design ID: 1871) containing
385,000 probes covering 24,134 promoters (1 kb and +500 bp
around the transcription start-site, on average). ChIP-chip
microarray data has been submitted to the GEO database for
public access (accession number pending)
DNA methylation analysis by HELP
The HELP assay was carried out as previously published[23]
with slight modifications. One microgram of genomic DNA was
digested overnight with either HpaII or MspI (NEB, Ipswich,
MA). On the following day the reactions were extracted once with
phenol-chloroform and resuspended in 11 mL of 10 mM Tris-HCl
pH 8.0 and the digested DNA was used to set up an overnight
ligation of the JHpaII adapter using T4 DNA ligase. The adapter-
ligated DNA was used to carry out the PCR amplification of the
HpaII and MspI-digested DNA as previously described[23]. Both
amplified fractions were submitted to Roche NimbleGen, Inc.
(Madison, WI) for labeling and hybridization onto a human HG17
custom-designed oligonucleotide array (50-mers) covering 25,626
HpaII amplifiable fragments (HAF) located at gene promoters and
imprinted regions. HpaII amplifiable fragments are defined as
genomic sequences contained between two flanking HpaII sites
found within 200–2,000 bp from each other. Each HAF on the
array is represent by 15 individual probes, randomly distributed
across the microarray slide. HELP microarray data has been
submitted to the GEO database for public access (accession
number pending)
Quantitative DNA methylation analysis by MassArray
Epityping
Validation of HELP microarray findings was carried out by
MALDI-TOF mass spectrometry using EpiTyper by MassArray
(Sequenom, CA) on bisulfite-converted DNA as previously
described[31]. MassArray primers were designed to cover the
Table 3. Canonical pathways rescued by the integrated
analysis
Pathway Integrated analysis (p value)
PI3K/AKT signaling 3.276e27
Chemokine signaling 1.066e23
Fc signaling 1.266e23
IL10 signaling 1.836e23
Nucleotide acid excision repair 7.46e23
doi:10.1371/journal.pone.0001882.t003
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flanking HpaII sites for a given HAF, as well as any other HpaII
sites found up to 2,000 bp upstream of the downstream site and up
to 2,000 bp downstream of the upstream site, in order to cover all
possible alternative sites of digestion (primer sequences available
on Table S2).
cDNA synthesis for Gene expression assays
Ten micrograms of total RNA were used to synthesize cDNA
using Superscript III (Invitrogen, Carlsbad, California) using the
manufacturer’s protocol for qRT-PCR. Double-stranded cDNA
synthesis for gene expression arrays was likewise carried out using
Invitrogen’s Superscript III, but a modified oligo-d(T) primer
(59GGCCAGTGAATTGTAATACGACTCACTATAGGGAGG
CGGTTTTTTTTTTTTTTTTTTTTTTTT-39) was used in lieu
of the kit’s oligo-d(T) primer. The second strand was synthesized for
2 hours at 16uC in a reaction containing 30 mL of 56second strand
buffer (Invitrogen), 90 mL of RNAse-free water, 3 mL dNTP
10 mM, 1 mL of BSA 1 mg/mL, 1 ul of E. coli DNA ligase 10 U/
mL (Invitrogen), 4 mL E. coli DNA polymerase I 10 U/mL
(Invitrogen) and 1 mL of RNase H 2 U/mL (Invitrogen). Finally,
2 mL of T4 DNA Polymerase 5 U/mL (Invitrogen) were added
and the reaction incubated at 16uC for another 10 minutes.
Reactions were cleaned with Qiagen’s Qiaquick PCR puri-
fication kit and submitted for labeling and hybridization onto
the NimbleGen standard human HG17 60mer 385,000 probe
gene expression array (2005-04-20_Human_60mer_1in2; design
ID: 1877). Gene expression microarray data has been sub-
mitted to the GEO database for public access (accession number
pending)
Quantitative real time PCR
The expression values of fifteen genes were validated by
quantitative RT-PCR (qRT-PCR). cDNA was synthesized using
the Superscript III First Strand kit from Invitrogen (Invitrogen’s
Superscript III) as per manufacturer’s protocol. The DDC(t)
method was used to determine relative gene expression levels [32]
using Power SYBRGreen from Applied Biosystems (Foster City,
CA) and a DNA Engine Opticon 2 real-time thermocycler from
Biorad (Hercules, CA). All primer sequences are available as
supplementary data (Table S2).
Sample labeling and Microarray hybridizations
All samples for microarray hybridization were processed at the
Roche NimbleGen Service Laboratory. Samples were labeled
using Cy-labeled random primers (9mers) and then hybridized
onto the corresponding microarray platform and scanned using a
GenePix 4000B scanner (Axon Instruments) as previously
described[33].
Microarray quality control
All microarray hybridizations were subjected to extensive
quality control using the following strategies. First, uniformity of
hybridization was evaluated using a modified version of a
previously published algorithm[34] adapted for the NimbleGen
platform, and any hybridization with strong regional artifacts was
repeated. Second, normalized signal intensities from each array
were compared against a 20% trimmed mean of signal intensities
across all arrays in that experiment, and any arrays displaying a
significant intensity bias that could not be explained by the biology
of the sample were excluded. Finally, replicate reproducibility was
estimated by using scatter plots and a Pearson correlation matrix,
and any clear outliers were excluded from further analysis
(Figures S1A, S1B and S1C).
Acetyl histone H3 lysine 9 ChIP-chip analysis
The H3K9 acetylation status at each promoter was computed
by taking the log-ratio between the probe intensities of the ChIP
product and input chromatin, which were co-hybridized on the
same assay. For each of the 24,134 promoter regions, we
computed the moving average of the log-ratio along its 15 probes
with a window size of 3 probes, and found the maximum value of
the moving averages of over each region covered by 15 probes.
The maximum values served as the summary of histone H3 lysine
9 acetylation of the promoter regions and were used to correlate
with gene expression profiles. All chips that passed primary quality
control showed a bimodal distribution with a distinct lower mode.
We took these lower modes to indicate non-enriched fragments,
and normalized across arrays by lining up these modes.
HELP data processing and analysis
Signal intensities at each HpaII amplifiable fragment were
calculated as a robust (25% trimmed) mean of their component
probe-level signal intensities. Any fragments found within the level
of background MspI signal intensity, measured as 2.5 mean-
absolute-differences (MAD) above the median of random probe
signals, were categorized as ‘‘failed.’’ These ‘‘failed’’ loci therefore
represent the population of fragments that did not amplify by
PCR, whatever the biological (e.g. genomic deletions and other
sequence errors) or experimental cause. On the other hand,
‘‘Methylated’’ loci were so designated when the level of HpaII
signal intensity was similarly indistinguishable from background.
PCR-amplifying fragments (those not flagged as either ‘‘methyl-
ated’’ or ‘‘failed’’) were normalized using an intra-array quantile
approach wherein HpaII/MspI ratios are aligned across density-
dependent sliding windows of fragment size-sorted data. Analysis
of normalized data revealed the presence of a bimodal
distribution. For each sample a cutoff was selected at the point
that more clearly separated these two populations and the data
were centered around this point. Each fragment was then
categorized as either methylated, if the centered log HpaII/MspI
ratio was less than zero, or hypomethylated if on the other hand
the log ratio was greater than zero.
Gene expression data processing and analysis
Raw data (.pair files) from the scanner were processed with
Roche NimbleGen’s version of the RMA algorithm (without
background correction) in NimbleScan 2.3 software. Gene
expression microarray assays were performed in quadruplicate
for each patient and 16 out of the 20 chips were selected on the
basis of standard quality metrics and uniformity of hybridization.
Next we selected 10 chips with the least evidence of technical
artifact compared with the median across all chips, and
constructed expression profiles for each of the five samples by
averaging each pair of replicate chips among these 10.
Descriptive statistics
Noise in gene expression and other microarray measures was
estimated as the standard error of the averages of the measures
across technical replicates. For the ChIP-chip arrays the average
standard error was 0.58. Gene expression values were processed
by NimbleScan 2.3 software using a quantile normalization, which
depresses estimates of variance at either end of the intensity
distribution relative to the middle. Most of our measures of interest
came from the middle range of intensities and their average
estimated standard error was 0.30. For HELP, the average
standard error of the quantile-normalized ratio estimates was 0.21.
For between-measures correlation analysis we selected genes
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whose measured standard deviation was at least 2.5 times the
standard error of the averages of replicates. Signal to noise ratio
(SNR) for all the platforms was defined as the ratio of variation
across samples compared to the variation between replicates of the
same sample
Clustering analysis
Unsupervised clustering of HELP and ChIP-chip data using
hierarchical clustering (correlation distance and complete linkage)
[35], correspondence analysis [36] and principal component
analysis [37] were performed using the open-source statistical
software R [38] and the BioConductor package MADE4 [39].
Since there are 10 distinct ways in which 5 samples can be divided
into two groups of 2 and 3 samples each, it was calculated that
there was a probability of 1 in 10 that this analysis would achieve
accurate separation of samples by lineage due to chance.
Supervised analysis was done using a standard T-test with
leukemic lineage (AML or ALL) as the dichotomous variable. A
significance level of p,0.02 was chosen for all three platforms. In
the case of the methylation data, a second criterion of a
difference.1.5 between the mean of the two populations was
added in order to increase the likelihood of detection of
biologically significant changes in methylation levels.
Pathway analysis
Using the Ingenuity Pathway Analysis software (IPA) (Redwood
City, CA) we carried out an analysis of the biological information
retrieved by each of the individual platforms alone, and compared
it to the information obtained by the integrated analysis of all three
platforms. Enrichment of genes associated with specific canonical
pathways was determined relative to the Ingenuity knowledge
database for each of the individual platforms and the integrated
analysis at a significance level of p,0.01. Biological networks
captured by the different microarray platforms were generated
using IPA and scored based on the relationship between the total
number of genes in the specific network and the total number of
genes identified by the microarray analysis.
Supporting Information
Text S1 Supplementary methods: Model for testing likelihood of
correlations between measures
Found at: doi:10.1371/journal.pone.0001882.s001 (0.06 MB
DOC)
Figure S1 Correlation matrix between replicate arrays and
different biological samples for each platform. Panel A: Correla-
tion matrix for all normalized HELP microarrays that passed
hybridization quality control. Panel B: Correlation matrix for
H3K9-acetyl ChIP-chip arrays that passed initial quality control.
Panel C: Correlation matrix for the ten gene expression arrays
selected for analysis after quality control assessment of all
hybridizations.
Found at: doi:10.1371/journal.pone.0001882.s002 (3.52 MB TIF)
Figure S2 Technical validations by single locus studies for each
microarray platform. Panel A: Correlation between qRT-PCR
findings (x axis: Delta C(t) to GAPDH) and gene expression arrays
(y axis: log2 intensity). The overall negative correlation (r =20.72)
confirms the good quality of the gene expression array data. Panel
B: Correlation between H3K9-acetyl ChIP-chip (x axis: log
H3K9ac/Input) and fold enrichment over non-specific IgG by
qChIP (y axis). Since H3K9ac ChIP-chip data display a bimodal
distribution, the lowest point between the two peaks (log
H3K9acetyl = 2.5) was selected as a cutoff for comparison with
qChIP. While most points below this cutoff point show minimal
enrichment by qChIP, points to the right of this cutoff clearly show
increasing amounts of enrichment with increasing log H3k9ac/
input values. Panel C: Relationship between DNA methylation by
HELP (x axis: log HpaII/MspI) and percent cytosine methylation
measured by MALDI-TOF mass spectrometry.
Found at: doi:10.1371/journal.pone.0001882.s003 (0.86 MB TIF)
Figure S3 Unsupervised clustering using of epigenomic data
principal component analysis (PCA). Unsupervised clustering of
DNAmethylation and H3K9 acetylation data using PCA separated
the leukemia samples according to lineage along the first principal
component. Panel A: Two-dimensional representation of PCA of
DNA methylation data. ALL samples (in red) readily cluster apart
from AML samples (in blue) along the first principal component (x
axis) (left); and heatmap of top 100 genes from the first principal
component (right). Genes are shown on the rows and samples on the
columns, and data were row-centered. Low values represented in
blue and high values in red. Panel B: Two-dimensional represen-
tation of PCA of H3K9-acetyl ChIP-chip data. ALL samples (in red)
and AML samples (in blue) readily segregated along the first
principal component (x axis) (left); and heatmap of top 100 genes
from the first principal component (right). Genes are shown on the
rows and samples on the columns, and data were row-centered.
Low values represented in blue and high values in red.
Found at: doi:10.1371/journal.pone.0001882.s004 (1.57 MB TIF)
Figure S4 Highest scoring networks from Ingenuity Pathway
Analysis comparing the individual platforms and the integrated
analysis. Biological gene networks identified as differentially
regulated in ALL versus AML. Networks were generated using
the genes identified through the analysis of the individual
platforms or from the genes identified when information from all
three platforms was integrated. Panel A: The top two scoring
networks identified using H3K9 acetylation data centered around
HoxA9 and APP. Genes that were present in the analysis gene list
appear colored in grey while genes identified indirectly appear in
white. Panel B: The top two scoring networks identified using
DNA methylation data centered around TNF and NFkB. Panel C:
The top two scoring networks identified using gene expression
data centered around TERT and NFkB. Panel D: The top two
scoring networks identified using data from the integration of all
three platforms centered around TNF and TP53. Panel E: The
biological network centering around MYC was among the highest
scoring networks (network #6) when using the integrated data,
while none of the individual platforms succeeded in identifying the
MYC network directly.
Found at: doi:10.1371/journal.pone.0001882.s005 (2.90 MB TIF)
Table S1 Canonical pathway analysis
Found at: doi:10.1371/journal.pone.0001882.s006 (0.03MBXLS)
Table S2 Primer sequences
Found at: doi:10.1371/journal.pone.0001882.s007 (0.05 MB
XLS)
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